中文
English
한국어
日本語
Español
Français
Русский
| 카탈로그 번호 | HB188016 |
|---|---|
| 설명 |
Monalizumab (HB188016) is a research-grade recombinant antibody targeting CD159. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| 종 반응성 | Human |
| 응용 분야 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 숙주 종 | Human |
| 클론성 | Monoclonal |
| 이소타입 | IgG4-kappa |
| 발현 시스템 | Mammalian cells |
| 타겟 | KLRC1, NKG2-A/NKG2-B type II integral membrane protein, NKG2-A/B-activating NK receptor, CD159 antigen-like family member A, CD159a, NK cell receptor A, NKG2A |
| 내독소 수준 | < 10 EU/mg |
| 순도 | >95% purity as determined by SDS-PAGE. |
| 정제 | Protein A/G purified from cell culture supernatant. |
| 등록번호 | P26715 |
| 형태 | Liquid |
| 저장 완충액 | 0.01M PBS pH 7.4 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 대체 이름 | IPH-2201, NN-8765, NNC-0141-0000-0100, NNC-141-01000, monolizumab, anti-NKG2A, humZ270, 1228763-95-8 |
| 배경 | NKG2-A/NKG2-B type II integral membrane protein (CD159a/KLRC1) is a ~26 kDa protein. Immune inhibitory receptor involved in self-nonself discrimination. In complex with KLRD1 on cytotoxic and regulatory lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib molecule HLA-E loaded with self-peptides derived from the signal sequence of classical MHC class Ia molecules. Enables cytotoxic cells to monitor the expression of MHC class I molecules in healthy cells and to tolerate self. Upon HLA-E-peptide binding, transmits intracellular signals through two immunoreceptor tyrosine-based inhibition motifs (ITIMs) by recruiting INPP5D/SHP-1 and INPPL1/SHP-2 tyrosine phosphatases to ITIMs, and ultimately opposing signals transmitted by activating receptors through dephosphorylation of proximal signaling molecules. Key inhibitory receptor on natural killer (NK) cells that regulates their activation and effector functions. 1. Sullivan, LC. et al. (2007) Immunity 27, 900-11. PMID: 18083576 2. Lin, Z. et al. (2023) Nature immunology 24, 1087-1097. PMID: 37264229 3. Valiante, NM. et al. (1997) Immunity 7, 739-51. PMID: 9430220 4. Braud, VM. et al. (1998) Nature 391, 795-9. PMID: 9486650 5. Kabat, J. et al. (2002) Journal of immunology (Baltimore, Md. : 1950) 169, 1948-58. PMID: 12165520 6. Le Dréan, E. et al. (1998) European journal of immunology 28, 264-76. PMID: 9485206 7. Kamiya, T. et al. (2019) The Journal of clinical investigation 129, 2094-2106. PMID: 30860984 8. Jabri, B. et al. (2002) Immunity 17, 487-99. PMID: 12387742 9. Bhagat, G. et al. (2008) The Journal of clinical investigation 118, 281-93. PMID: 18064301 |
| 참고사항 | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG4 (S228P) Recombinant Isotype Control Antibody (SAA0184) (HP298107) |
SDS-PAGE for Research Grade Monalizumab.
+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206
